Faculty List/Disclosures

Article Outline

• Guest Editor
• Faculty
• Faculty Disclosures

Managing Cardiometabolic Risk: Will New Approaches Improve Success?

Back to Article Outline

Guest Editor 

Scott M. Grundy, MD, PhD

Director, Center for Human Nutrition

Chairman, Department of Clinical Nutrition

University of Texas Southwestern Medical Center

Dallas, Texas

Back to Article Outline

Faculty 

Steven M. Haffner, MD

Professor of Medicine

Department of Medicine and Clinical Epidemiology

University of Texas Health Science Center

San Antonio, Texas

Michael D. Jensen, MD

Professor of Medicine

Endocrine Research Unit

Division of Endocrinology, Diabetes, Metabolism, & Nutrition

Mayo Clinic College of Medicine and Obesity Treatment Clinic

Rochester, Minnesota

George Kunos, MD, PhD

National Institute on Alcohol Abuse and Alcoholism

National Institutes of Health

Bethesda, Maryland

Back to Article Outline

Faculty Disclosures 

The authors who contributed to this publication have disclosed the following industry relationships:

Scott M. Grundy, MD, PhD, has served as a consultant to Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and Company, Fournier Pharma, GlaxoSmithKline, Kos Pharmaceuticals, Inc., Merck & Co., Inc., Merck/Schering-Plough Pharmaceuticals, Pfizer Inc, Sankyo Pharma Inc., and sanofi-aventis; and has worked as an investigator on research grants awarded to the University of Texas Southwestern Medical Center for Abbott Laboratories, Kos Pharmaceuticals, Inc., and Merck & Co., Inc.

Steven M. Haffner, MD, has served as a consultant to and has received honoraria from GlaxoSmithKline, Merck Sharp & Dohme, Pfizer Inc, and Sanofi-Synthelabo Inc.

Michael D. Jensen, MD, has served as a consultant to EnteroMedics Inc., Metabolic Pharmaceuticals Ltd., sanofi-aventis, and Shionogi USA, Inc.

George Kunos, MD, PhD, reports nothing to disclose.